A Phase III, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study of Atezolizumab (Anti-PD-L1 Antibody) as Adjuvant Therapy in Patients With Renal Cell Carcinoma at High Risk of Developing Metastasis Following Nephrectomy
A Phase III, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study of Atezolizumab (Anti-PD-L1 Antibody) as Adjuvant Therapy in Patients With Renal Cell Carcinoma at High Risk of Developing Metastasis Following Nephrectomy
This is a Phase III, multicenter, randomized, placebo-controlled, double-blind study to evaluate the efficacy and safety of atezolizumab versus placebo in participants with RCC who are at high risk of disease recurrence following nephrectomy.
Inclusion Criteria:
Exclusion Criteria:
Chicago, Illinois 60637, United States
Maywood, Illinois 60151, United States
Nashville, Tennessee 37232, United States
Caba, C1118AAT, Argentina
Salzburg, 5020, Austria
Vienna, 1090, Austria
Sherbrooke, Quebec J1H 5N4, Canada
Praha 4 - Krc, 140 59, Czechia
Hanover, 30625, Germany
Heidelberg, 69120, Germany
Homburg/Saar, 66424, Germany
Dublin, 24, Ireland
Bologna, Emilia-Romagna 40138, Italy
Meldola, Emilia-Romagna 47014, Italy
Krakow, 31-115, Poland
Późna, 60-569, Poland
Moscow, Moscow Oblast 125248, Russia
Moscow, Moscow Oblast 143423, Russia
Santiago de Compostela, LA Coruña 15706, Spain
Oviedo, Principality of Asturias 33011, Spain
Bangkok, 10330, Thailand
Adana, 01230, Turkey (Türkiye)
Sihhiye/Ankara, 06230, Turkey (Türkiye)
Kharkiv, Kharkiv Governorate 61037, Ukraine
Lviv, 79034, Ukraine